Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evorpacept + enfortumab vedotin
- Development stage
- Unknown
- Lead developer
- ALX Oncology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Evorpacept + enfortumab vedotin** is a combination therapy tested in advanced or metastatic urothelial carcinoma (most commonly bladder cancer), particularly for patients progressed on platinum-based chemotherapy and immune checkpoint inhibitors[1][3][4]. - **Evorpacept (ALX148)** is a high-affinity CD47 blocking fusion protein designed to block the CD47/SIRPα "do not eat me" signal on tumor cells and stimulate the immune system, enhancing antibody-dependent cellular phagocytosis (ADCP) within the tumor microenvironment[3][1]. - **Enfortumab vedotin (Padcev)** is an antibody-drug conjugate (ADC) targeting Nectin-4 on cancer cells. After binding, it delivers a cytotoxic agent (MMAE), causing direct cell death[1][3]. - The combination intends to leverage evorpacept's immune-enhancing effects with enfortumab vedotin's targeted cytotoxicity, with phase 1 data supporting safety and preliminary antitumor activity[3][1][4]. - Developed for advanced/metastatic urothelial carcinoma; trial designs use intravenous administration[3].
- Brand names
- Padcev (for enfortumab vedotin)
- Other names
- ALX148 + Padcevevorpacept and enfortumab vedotinevorpacept plus enfortumab vedotin
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)CD47 (Cluster of Differentiation 47)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)SIRPA (Signal-regulatory protein alpha)
Beyond the preview
Go deeper on evorpacept + enfortumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evorpacept + enfortumab vedotin.